Araris Biotech AG establishes Scientific Advisory Board

  • Rakesh Dixit, John Lambert and L. Nathan Tumey appointed as members

Zurich, Switzerland, October 3rd, 2019Araris Biotech AG announced today the appointment of Dr. Rakesh Dixit, Dr. John Lambert and Dr. L. Nathan Tumey as members of its Scientific Advisory Board.

Dr. Rakesh Dixit worked between 2006 - 2019 as Vice President, R&D, Global Head, Biologics Safety at Medimmune (AstraZeneca). In this position, he was responsible for providing guidance on research and development of biological products, including discovery, nonclinical toxicology/safety and translational sciences support for all AstraZeneca biologics products such as monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific antibodies and vaccines. Dr. Dixit has published more than 80 papers in renowned international journals and has given over 130 invited lectures/presentations/workshops in national and international meetings. Previously, he worked with Merck (1992-2005) contributing to the successful filing of many blockbuster drugs and after that he was associated with Johnson & Johnson PRD, La Jolla (2005-2006).

Dr. Dixit conducted extensive graduate and post-graduate training in Toxicology–Biochemistry with both Indian and US Institutions (Case Western Reserve University, Medical College of Ohio, University of Nebraska) and is board certified in Toxicology from the American Board of Toxicology, Inc. since 1992.

Dr. John Lambert was the Chief Scientific Officer at ImmunoGen and played an important role in translating the technology of ImmunoGen into ADC clinical development programs. These efforts ultimately led to Kadcyla®, one of the first ADCs that was approved by the FDA. He is the author and co-author of more than 120 peer-reviewed scientific publications. In 2016, Dr. Lambert was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). Prior to joining ImmunoGen, he served as Assistant Professor of Pathology at the Dana-Farber Cancer Institute of the Harvard Medical School.

Dr. Lambert holds a PhD in Biochemistry from the University of Cambridge in England and completed his postdoctoral work at the University of California at Davis and Glasgow University in Scotland.

Dr. L. Nathan Tumey is an assistant professor of medicinal chemistry in the School of Pharmacy and Pharmaceutical Sciences at Binghamton University. He joined Binghamton University in 2017, following 15 years of experience in the pharmaceutical and biotechnology industry. Between 2009 - 2017 he was a team leader for the ADC discovery efforts at Pfizer. In this role, he led a group of bioconjugation and bioanalytical scientists that designed and synthesized antibody-drug conjugates for use in oncology applications. He received his PhD in chemistry from Duke University in 2001, under the supervision of Michael Pirrung. His research team at Binghamton University focuses on the application of antibody-drug conjugates and related modalities for the treatment of auto-immune disorders and rare diseases. Additionally, his lab investigates bioconjugate stability, ADC linker design and new modalities for targeted drug-delivery.

For further details, please contact:

Araris Biotech AG

Dr. Philipp Spycher, CEO

About Araris Biotech AG:

Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology. Araris' innovative platform allows for the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering. The resulting ADCs have a well-defined drug-to-antibody ratio, are stable and monomeric. All these favorable properties contribute to the high efficacy and low level of toxicity observed so far. In summary, the straightforward drug conjugation, versatility of the technology and high in vivo efficacy enable the generation of ADC compounds for the treatment of patients with a high unmet medical need.

For more information, please visit:

Back to news